These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 35947386)

  • 1. Racial Differences in Patient-Reported Symptoms and Adherence to Adjuvant Endocrine Therapy Among Women With Early-Stage, Hormone Receptor-Positive Breast Cancer.
    Hu X; Walker MS; Stepanski E; Kaplan CM; Martin MY; Vidal GA; Schwartzberg LS; Graetz I
    JAMA Netw Open; 2022 Aug; 5(8):e2225485. PubMed ID: 35947386
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of Clinical Symptoms by Race Among Women With Early-Stage, Hormone Receptor-Positive Breast Cancer Before Starting Chemotherapy.
    Hu X; Chehal PK; Kaplan C; Krukowski RA; Lan RH; Stepanski E; Schwartzberg L; Vidal G; Graetz I
    JAMA Netw Open; 2021 Jun; 4(6):e2112076. PubMed ID: 34061200
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Remote Monitoring App for Endocrine Therapy Adherence Among Patients With Early-Stage Breast Cancer: A Randomized Clinical Trial.
    Graetz I; Hu X; Kocak M; Krukowski RA; Anderson JN; Waters TM; Curry AN; Robles A; Paladino A; Stepanski E; Vidal GA; Schwartzberg LS
    JAMA Netw Open; 2024 Jun; 7(6):e2417873. PubMed ID: 38935379
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adherence to Adjuvant Endocrine Therapy in Insured Black and White Breast Cancer Survivors: Exploring Adherence Measures in Patient Data.
    Sheppard VB; He J; Sutton A; Cromwell L; Adunlin G; Salgado TM; Tolsma D; Trout M; Robinson BE; Edmonds MC; Bosworth HB; Tadesse MG
    J Manag Care Spec Pharm; 2019 May; 25(5):578-586. PubMed ID: 31039059
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Racial differences in long-term adjuvant endocrine therapy adherence and mortality among Medicaid-insured breast cancer patients in Texas: Findings from TCR-Medicaid linked data.
    Farias AJ; Wu WH; Du XL
    BMC Cancer; 2018 Dec; 18(1):1214. PubMed ID: 30514270
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Race Differences in Patient-Reported Symptoms during Chemotherapy among Women with Early-Stage Hormone Receptor-Positive Breast Cancer.
    Hu X; Kaplan CM; Martin MY; Walker MS; Stepanski E; Schwartzberg LS; Vidal GA; Graetz I
    Cancer Epidemiol Biomarkers Prev; 2023 Feb; 32(2):167-174. PubMed ID: 36166516
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Initiation and adherence to adjuvant endocrine therapy among urban, insured American Indian/Alaska Native breast cancer survivors.
    Emerson MA; Achacoso NS; Benefield HC; Troester MA; Habel LA
    Cancer; 2021 Jun; 127(11):1847-1856. PubMed ID: 33620753
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of Endocrine Therapy Initiation Timeliness With Adherence and Continuation in Low-Income Women With Breast Cancer.
    Sood N; Liu Y; Lian M; Greever-Rice T; Lucht J; Schmaltz C; Colditz GA
    JAMA Netw Open; 2022 Aug; 5(8):e2225345. PubMed ID: 35921108
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Race and Patient-reported Symptoms in Adherence to Adjuvant Endocrine Therapy: A Report from the Women's Hormonal Initiation and Persistence Study.
    Sheppard VB; Sutton AL; Hurtado-de-Mendoza A; He J; Dahman B; Edmonds MC; Hackney MH; Tadesse MG
    Cancer Epidemiol Biomarkers Prev; 2021 Apr; 30(4):699-709. PubMed ID: 33514603
    [TBL] [Abstract][Full Text] [Related]  

  • 10. THRIVE study protocol: a randomized controlled trial evaluating a web-based app and tailored messages to improve adherence to adjuvant endocrine therapy among women with breast cancer.
    Paladino AJ; Anderson JN; Krukowski RA; Waters T; Kocak M; Graff C; Blue R; Jones TN; Buzaglo J; Vidal G; Schwartzberg L; Graetz I
    BMC Health Serv Res; 2019 Dec; 19(1):977. PubMed ID: 31856812
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association Between Out-Of-Pocket Costs, Race/Ethnicity, and Adjuvant Endocrine Therapy Adherence Among Medicare Patients With Breast Cancer.
    Farias AJ; Du XL
    J Clin Oncol; 2017 Jan; 35(1):86-95. PubMed ID: 28034069
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adherence trajectories of adjuvant endocrine therapy in the five years after its initiation among women with non-metastatic breast cancer: a cohort study using administrative databases.
    Lambert-Côté L; Bouhnik AD; Bendiane MK; Bérenger C; Mondor M; Huiart L; Lauzier S
    Breast Cancer Res Treat; 2020 Apr; 180(3):777-790. PubMed ID: 32086655
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of the Quality of Adjuvant Endocrine Therapy Delivery for Breast Cancer Care in the United States.
    Daly B; Olopade OI; Hou N; Yao K; Winchester DJ; Huo D
    JAMA Oncol; 2017 Jul; 3(7):928-935. PubMed ID: 28152150
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of patient race and geographical factors on initiation and adherence to adjuvant endocrine therapy in medicare breast cancer survivors.
    Camacho FT; Tan X; Alcalá HE; Shah S; Anderson RT; Balkrishnan R
    Medicine (Baltimore); 2017 Jun; 96(24):e7147. PubMed ID: 28614244
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Are breast cancer patients with suboptimal adherence to cardiovascular treatment more likely to discontinue adjuvant endocrine therapy? Competing risk survival analysis in a nationwide cohort of postmenopausal women.
    Artignan J; Capmas P; Panjo H; Constantinou P; Pelletier-Fleury N
    BMC Med; 2023 Nov; 21(1):463. PubMed ID: 38001491
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factors influencing adherence to adjuvant endocrine therapy in breast cancer-treated women: using real-world data to inform a switch from acute to chronic disease management.
    Cavazza M; Banks H; Ercolanoni M; Cukaj G; Bianchi G; Capri G; Longo F
    Breast Cancer Res Treat; 2020 Aug; 183(1):189-199. PubMed ID: 32591986
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Testing a behavioral intervention to improve adherence to adjuvant endocrine therapy (AET).
    Shelby RA; Dorfman CS; Bosworth HB; Keefe F; Sutton L; Owen L; Corsino L; Erkanli A; Reed SD; Arthur SS; Somers T; Barrett N; Huettel S; Gonzalez JM; Kimmick G
    Contemp Clin Trials; 2019 Jan; 76():120-131. PubMed ID: 30472215
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Physical activity, health-related quality of life, and adjuvant endocrine therapy-related symptoms in women with hormone receptor-positive breast cancer.
    Sheppard VB; Dash C; Nomura S; Sutton AL; Franco RL; Lucas A; Ross M; Adams-Campbell L
    Cancer; 2020 Sep; 126(17):4059-4066. PubMed ID: 32614992
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of patient subgroups who benefit from a behavioral intervention to improve adjuvant endocrine therapy adherence: a randomized-controlled trial.
    Walsh EA; Post K; Massad K; Horick N; Antoni MH; Penedo FJ; Safren SA; Partridge AH; Peppercorn J; Park ER; Temel JS; Greer JA; Jacobs JM
    Breast Cancer Res Treat; 2024 Apr; 204(3):547-559. PubMed ID: 38231313
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adherence to adjuvant endocrine therapy for breast cancer: a qualitative exploration of attribution of symptoms among post-menopausal women.
    Lee AY; Lyons AT; Makris V; Kamaraju S; Stolley MR; Neuner JM; Flynn KE
    Support Care Cancer; 2024 Apr; 32(4):265. PubMed ID: 38565669
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.